ETFS S&P Biotech ETF


ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. healthcare biotechnology companies. These companies are engaged in the research, development and manufacturing of products based on genetic analysis and genetic engineering. Examples include the development of immunotherapy treatments and vaccines to treat human diseases.


About CURE

CURE aims to provide investors with a return that, before fees and expenses, tracks the performance of the S&P Biotechnology Select Industry Index. CURE uses a full-replication strategy to track the index, meaning that it holds all of the shares that make up the index. It is equal weighted, meaning each holding makes up the same portion of the portfolio and therefore contributes equally to overall performance.

To be eligible for inclusion in the index, companies must be part of the biotechnology sub-industry of the U.S. healthcare sector and meet minimum market capitalisation and liquidity requirements.


Why consider CURE


Simple, low cost exposure to the biotechnology sub-industry.


Access to the U.S. biotechnology market benefitting from the FDA drug approval and U.S. patent system.


Exposure to medical advances and potential mergers & acquisitions.



What is biotechnology?

Biotechnology includes companies primarily engaged in the research, development, manufacturing and/or marketing of products bas